



## CHEPLAPHARM CLOSES ANOTHER PRODUCT PORTFOLIO ACQUISITION

*Greifswald, 11/02/2020*

This week Cheplapharm closed another deal of a product bundle which contains six molecules and 12 related brands, focused on the treatment of cardiologic diseases. The acquisition was signed in June 2020 with one of Cheplapharm's long standing partners. The APIs of the referring products are Colesevelam, Molsidomine, Acebutolol, Nadolol, Propranolol and Sotalol. The asset deal contains product registrations, intellectual property, certain contracts and inventory mainly valid for European Countries. The deal does not include any transfer of manufacturing facilities or employees.

"This investment underlines the value of our platform enabling us to further integrate products in our portfolio", said CHEPLAPHARM's CEO Sebastian F. Braun.

### About CHEPLAPHARM

CHEPLAPHARM is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy. Working closely with its business partners, CHEPLAPHARM achieves sustainable annual growth rates. CHEPLAPHARM has been one of the fastest-growing pharmaceutical companies in Europe.

Please refer to [www.cheplapharm.com](http://www.cheplapharm.com) for additional information.

### Press office:

CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | [presse\(at\)cheplapharm.com](mailto:presse(at)cheplapharm.com)